🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas ow.ly/CXRr50TkrZB #drugadvances #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia nejm.org/doi/full/10.10…

#Myeloma Paper of the Day: Factors impeding organ recovery despite a deep hematological response in patients with systemic AL #amyloidosis varied depending on the organ, and included detectable residual clonal disease: pubmed.ncbi.nlm.nih.gov/39275899/. #mmsm

Transformation of marginal zone lymphoma to Hodgkin lymphoma ow.ly/5lkM50Tkr5t #lymphoidneoplasia

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper buff.ly/4enfPdw Martin Kaiser Simon Stern Christina Messiou @myelomauk

Acalabrutinib plus venetoclax and rituximab resulted in high clinical and molecular response rates in patients with TN MCL. ow.ly/nc3550TksTM #clinicaltrialsandobservations #lymphoidneoplasia

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome ow.ly/EWzc50Tmshe #specialreport #plateletsandthrombopoiesis

Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice buff.ly/3ZpBnC5

🕰️The countdown to #IMS24 has begun—just one week left! Don’t let your colleagues have all the fun—secure your spot today! Whether you’re attending in Rio de Janeiro or virtually, visit rb.gy/1h136x to register!

#Myelopma Paper of the Day: Pirtobrutinib blocks p-ERK1/2, ERK1/2-driven inflammatory cytokines, and overcomes paracrine-mediated resistance in MYD88Mut #Waldenstrom macroglobulinemia lymphoma cells expressing mutated BTKCys481: pubmed.ncbi.nlm.nih.gov/39295138/. #mmsm

Young male with CML lymphoid blast crisis, T315I mutation Post Allo HSCT 10/10, on Ponatinib maintenance Day 365, post transplant MRD positive(0.43%), BCR ABL Negative Chimerism 100% What next to do?

Today Sept 22nd is observed world wide as World CML Day. Chronic Myeloid Leukemia is a rare cancer which once fatal has now been converted into a chronic, manageable condition. CML patients on life long targeted therapy need regular monitoring & counseling to ensure compliance

#ChildhoodCancerAwarenessMonth Day 22 Acute promyelocytic leukemia #APML From most dreaded to most curable AML in last 50 years ATRA is life saving as it helps prevent death due to bleeding induced by leukemia Low dose arsenic can cure this cancer NO CHEMO needed

Today, we shine a light on Chronic Myeloid Leukemia (CML) and the incredible strength of those affected by it. CML is a type of cancer that affects the blood and bone marrow, and it’s important to spread awareness about its symptoms, treatments, and the importance of early

Patients with MM patients have increased CD16/CD226Low NK cell subsets characterized by adhesion defects and reduced effector functions. ow.ly/ZF6T50Tr8n9 #immunobiologyandimmunotherapy #clinicaltrialsandobservations #lymphoidneoplasia #multiplemyeloma

#IMS24 so excited to see this map of upcoming Myeloma Society #MMsm myeloma meetings! Canada, Scotland, India, US, Finland, and Türkiye 🤩 Save the dates now!

IMS 2024 @ Rio de Janerio, Brazil, 🇧🇷

IMS 2024 @ Rio de Janerio, Brazil

Day 2, IMS 2024